NUS vs. CORT

Last updated Jun 23, 2026

NUS (Nu Skin Enterprises, Inc.) and CORT (Corcept Therapeutics Incorporated) are both stocks. NUS operates in Household & Personal Products (Consumer Defensive), while CORT operates in Biotechnology (Healthcare). Over the past 10 years, NUS returned -17.12%/yr vs 31.34%/yr for CORT. At a 0.17 correlation, their price movements are largely independent.

Performance

NUS vs. CORT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nu Skin Enterprises, Inc. (NUS) and Corcept Therapeutics Incorporated (CORT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NUS achieves a -47.13% return, which is significantly lower than CORT's 129.05% return. Over the past 10 years, NUS has underperformed CORT with an annualized return of -17.12%, while CORT has yielded a comparatively higher 31.34% annualized return.

NUS

• 1D: -0.40%
• 1M: -14.83%
• YTD: -47.13%
• 6M: -49.64%
• 1Y: -33.40%
• 3Y*: -44.26%
• 5Y*: -36.42%
• 10Y*: -17.12%

CORT

• 1D: -0.25%
• 1M: 32.36%
• YTD: 129.05%
• 6M: -6.34%
• 1Y: 11.67%
• 3Y*: 53.92%
• 5Y*: 29.06%
• 10Y*: 31.34%

*Multi-year figures are annualized to reflect compound growth (CAGR)

NUS vs. CORT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NUS Nu Skin Enterprises, Inc.	-47.13%	43.29%	-63.67%	-51.07%	-13.92%	-4.32%	38.67%	-30.98%	-8.32%	46.55%
CORT Corcept Therapeutics Incorporated	129.05%	-30.94%	55.14%	59.92%	2.58%	-24.31%	116.20%	-9.43%	-26.02%	148.76%

Correlation

The correlation between NUS and CORT is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.05
Correlation (3Y) Calculated over the trailing 3-year period	0.19
Correlation (5Y) Calculated over the trailing 5-year period	0.22
Correlation (10Y) Calculated over the trailing 10-year period	0.20
Correlation (All Time) Calculated using the full available price history since Apr 14, 2004	0.17

The correlation between NUS and CORT shifts across timeframes, from 0.05 (1 year) to 0.22 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap NUS : $247.11M CORT : $8.32B
EPS NUS : $1.10 CORT : $0.41
PE Ratio NUS : 4.57 CORT : 194.37
PEG Ratio NUS : 0.01 CORT : 96.82
PS Ratio NUS : 0.17 CORT : 12.03
PB Ratio NUS : 0.31 CORT : 13.05
Total Revenue (TTM) NUS : $1.44B CORT : $769.10M
Gross Profit (TTM) NUS : $998.90M CORT : $755.64M
EBITDA (TTM) NUS : $115.40M CORT : $3.66M

Return for Risk

NUS vs. CORT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUS

NUS Risk / Return Rank: 17
NUS Sharpe Ratio Rank: 15
NUS Sortino Ratio Rank: 17
NUS Omega Ratio Rank: 16
NUS Calmar Ratio Rank: 22
NUS Martin Ratio Rank: 17

CORT

CORT Risk / Return Rank: 50
CORT Sharpe Ratio Rank: 48
CORT Sortino Ratio Rank: 49
CORT Omega Ratio Rank: 60
CORT Calmar Ratio Rank: 47
CORT Martin Ratio Rank: 46

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NUS vs. CORT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nu Skin Enterprises, Inc. (NUS) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	NUS	CORT	Difference
Sharpe ratio: Return per unit of total volatility	-0.64	0.15	-0.79
Sortino ratio: Return per unit of downside risk	-0.69	0.76	-1.45
Omega ratio: Gain probability vs. loss probability	0.91	1.16	-0.25
Calmar ratio: Return relative to maximum drawdown	-0.56	0.18	-0.74
Martin ratio: Return relative to average drawdown	-1.13	0.33	-1.46

NUS vs. CORT - Sharpe Ratio Comparison

The current NUS Sharpe Ratio is -0.64, which is lower than the CORT Sharpe Ratio of 0.15. The chart below compares the historical Sharpe Ratios of NUS and CORT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

NUS vs. CORT - Drawdown Comparison

The maximum NUS drawdown since its inception was -94.63%, roughly equal to the maximum CORT drawdown of -94.29%. Use the drawdown chart below to compare losses from any high point for NUS and CORT.

Drawdown Indicators

	NUS	CORT	Difference
Max Drawdown Largest peak-to-trough decline	-94.63%	-94.29%	-0.34%
Max Drawdown (1Y) Largest decline over 1 year	-60.32%	-64.40%	+4.08%
Max Drawdown (3Y) Largest decline over 3 years	-83.49%	-71.85%	-11.64%
Max Drawdown (5Y) Largest decline over 5 years	-89.79%	-71.85%	-17.94%
Max Drawdown (10Y) Largest decline over 10 years	-92.37%	-71.85%	-20.52%
Current Drawdown Current decline from peak	-94.61%	-30.21%	-64.40%
Average Drawdown Average peak-to-trough decline	-48.14%	-53.43%	+5.29%
Ulcer Index Depth and duration of drawdowns from previous peaks	29.67%	35.39%	-5.72%

Volatility

NUS vs. CORT - Volatility Comparison

The current volatility for Nu Skin Enterprises, Inc. (NUS) is 10.08%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 13.61%. This indicates that NUS experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NUS	CORT	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.08%	13.61%	-3.53%
Volatility (6M) Calculated over the trailing 6-month period	33.46%	85.06%	-51.60%
Volatility (1Y) Calculated over the trailing 1-year period	52.82%	77.18%	-24.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	47.06%	74.59%	-27.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	49.07%	67.22%	-18.15%

Dividends

NUS vs. CORT - Dividend Comparison

NUS's dividend yield for the trailing twelve months is around 4.80%, while CORT has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CORT Corcept Therapeutics Incorporated	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NUS Nu Skin Enterprises, Inc.	4.80%	2.49%	3.48%	8.03%	3.65%	3.00%	2.75%	3.61%	2.38%	2.11%	2.97%	3.69%

Financials

NUS vs. CORT - Profitability Comparison

The chart below illustrates the profitability comparison between Nu Skin Enterprises, Inc. and Corcept Therapeutics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NUS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Nu Skin Enterprises, Inc. reported a gross profit of 214.46M and revenue of 320.61M. Therefore, the gross margin over that period was 66.9%.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.

NUS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Nu Skin Enterprises, Inc. reported an operating income of 4.03M and revenue of 320.61M, resulting in an operating margin of 1.3%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.

NUS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Nu Skin Enterprises, Inc. reported a net income of 1.84M and revenue of 320.61M, resulting in a net margin of 0.6%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.

Frequently Asked Questions

Can I hold both NUS and CORT in my portfolio?

NUS and CORT have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NUS or CORT?

CORT has higher volatility (13.61%) compared to NUS (10.08%). In terms of maximum drawdown, NUS dropped -94.63% vs CORT's -94.29%.

Which has better risk-adjusted returns?

CORT currently has the higher Sharpe Ratio (0.15 vs -0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.